Board of Directors
Dr. Behzad Aghazadeh has served as Chairman of our Board of Directors since March 2017 and brings more than 20 years of experience in the biopharmaceutical industry, across various disciplines. The majority of Behzad’s career has been spent in healthcare investing, and he currently serves as Managing Partner and Portfolio Manager of Avoro Capital Advisors, LLC, an SEC registered investment manager. Behzad began his career in healthcare as a research scientist, later joining Booz Allen (now a unit of PricewaterhouseCoopers) as a management consultant, where he led major strategic and operational initiatives for companies in the pharmaceutical and biotechnology industries.
Dr. Aghazadeh holds a Masters in Physics from Ludwig-Maximilians University and a Ph.D. in Biochemistry & Biophysics from Cornell University.
Year Joined: 2017
Bob Azelby was formerly the President and CEO of Alder BioPharmaceuticals, a clinical-stage biopharmaceutical company that was acquired by H. Lundbeck for $2.4 billion in 2019. Previously, he was Juno Therapeutics’ Executive Vice President and Chief Commercial Officer, participating in the management of all aspects of Juno’s operations and personally accountable for leading and developing Juno’s commercial capabilities. Juno was acquired by Celgene for $9 billion in 2018. Prior to Juno, Bob was the Vice President and General Manager of Amgen’s US Oncology Business Unit, representing $6.5 billion in net revenue. Over his 15-year career with Amgen, Bob held numerous sales and marketing positions. In addition to Clovis Oncology, Bob is a member of the Immunomedics Board of Directors.
He received his undergraduate degrees in economics and religious studies from the University of Virginia and his Master of Business Administration from Harvard University.
Year Joined: 2020
Mr. Scott Canute joined the Immunomedics board in 2017. Mr. Canute has more than 34 years of experience in the biopharmaceutical industry, previously serving as President of Global Manufacturing and Corporate Operations of Genzyme Corporation from 2010 until 2011, where he led a major turnaround in manufacturing in order to ensure the on-going supply of life-saving products that were in short supply and developed and implemented a comprehensive manufacturing strategy including a revamped global governance system. Prior to joining Genzyme, Mr. Canute spent 25 years at Eli Lilly and Company, where he served as President, Global Manufacturing Operations from 2004 until 2007. During his tenure at Eli Lilly, Mr. Canute directed all manufacturing and supply chain activities for the company’s global operations, which spanned 24 international manufacturing sites and 80+ contract manufacturing operations and managed a $3.7 billion budget.
Mr. Canute currently serves on the Board of Directors for Akebia Therapeutics, Inc., a biopharmaceutical company focused on kidney disease through the biology of hypoxia-inducible factor (HIF); Flexion Therapeutics, Inc., Proteon Therapeutics, Inc., and Oncobiologics, Inc. He previously served as a Director for Allocure Inc. Mr. Canute has also served as a member of the Board of Directors of the National Association of Manufacturers, the Indiana Manufacturers Association and the Tauber Manufacturing Institute-University of Michigan.
Mr. Canute holds a B.S. Chemical Engineering degree from the University of Michigan and an M.B.A. from Harvard Business School.
Year Joined: 2017
Dr. Khalid Islam has been a member of the Board of Directors of Immunomedics since 2017. He has over 30 years of experience in drug discovery and development of anti-infectives, hematology/oncology and CNS in the pharmaceutical and biotechnology industry and currently serves as the Managing Director of Life Sciences Management GmbH, a position he has held since 2014.
Previously, Dr. Islam served as Chairman and CEO of Gentium S.p.A., a Nasdaq-listed pharmaceutical company, from 2009 until 2014 (merged with Jazz Pharmaceuticals, plc.) Dr. Islam had also served as President and CEO of Arpida AG and held various positions at Sanofi-Aventis (f/k/a HMR & MMD). He holds several patents and has published over 80 articles in leading journals.
He is an advisor to the venture group Kurma Biofund (Paris) and a founder/co-founder of Sirius Healthcare Partners GmbH (Zurich, Switzerland), PrevAbr LLC (D.C., USA), BioAim LLC (L.A., USA), Nuprim Inc. (D.C., USA), Exbaq LLC (L.A., USA), Gain Therapeutics (Lugano, Switzerland) & Life Sciences Management GmbH (Zug, Switzerland). Dr. Islam also currently serves as the Chairman of the Board of Directors for Minoryx Therapeutics, Fennec Pharma, Inc. (Nasdaq, FENC) and Gain Therapeutics.
Dr. Islam holds an undergraduate degree from Chelsea College and a Ph.D. from Imperial College, University of London.
Year Joined: 2017
Barbara Duncan has served as a Director on our Board of Directors since March 2019. Ms. Duncan served as the chief financial officer of Intercept Pharmaceuticals Inc. from 2009 to 2016 and as treasurer from 2010 to 2016. From 2001 to 2009, Ms. Duncan served as chief financial officer and then chief executive officer at DOV Pharmaceutical, Inc. Previously, Ms. Duncan served as a vice president of Lehman Brothers Inc. in its corporate finance division from 1998 to 2001. She serves on the board of directors of Adaptimmune Therapeutics plc, Aevi Genomic Medicine, Inc., Jounce Therapeutics, Inc., ObsEva plc and Ovid Therapeutics, Inc.
Ms. Duncan holds a B.S. degree from Louisiana State University and an M.B.A. from the Wharton School.
Year Joined: 2019
Dr. Charles M. Baum joined the Immunomedics Board of Directors in 2019. Dr. Baum was appointed President and Chief Executive Officer and Board Member of Mirati Therapeutics (NASDAQ: MRTX) in November 2012. During his time at Mirati, he has been responsible for moving the company to the United States, listing the company on NASDAQ and establishing its headquarters in San Diego, California. In addition, he has built a world-class precision oncology leadership team and transformed Mirati into a company focused on the innovative, targeted development of Mirati’s receptor tyrosine kinase, histone deacetylase inhibitor and KRAS inhibitors in advanced cancer patients with unmet medical needs. Since late 2012 Dr. Baum has raised over $600M and increased the valuation of the company from less than $100M to $~3.0B.
In addition to his director role at Mirati, Dr. Baum is a Member of the Board at Array Biopharma (NASDAQ: ARRY) since 2014. He serves as Chair of the Governance Committee (2017 – present) and is a member of the Research and Development Committee (2014 – present) and served on the Audit Committee (2014 to 2017).
Prior to joining Mirati, Dr. Baum was Senior Vice President and Chief Medical Officer for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division. Dr. Baum was at Pfizer from 2003 until joining Mirati in 2012, serving in roles of increasing responsibility including as Vice President and Head of Oncology Development and as Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center.
Dr. Baum holds M.D. and Ph.D. (Immunology) degrees from Washington University School of Medicine and post-graduate training from Stanford University.
Year Joined: 2019
Mr. Peter Barton Hutt joined the Immunomedics Board of Directors in 2017 and has brought extensive experience in FDA regulation of new drugs. He began his legal career at Covington & Burling LLP in 1960 and remains there today. Mr. Hutt served as Chief Counsel of FDA during 1971-1975 and for the past 26 years has taught a full course on Food and Drug Law at Harvard Law School. He has been a member of the National Academy of Medicine since it was established in 1971.
Mr. Peter holds an Undergraduate degree from Yale College, Law degree from Harvard Law School, and Master of Law degree from NYU Law School.
Year Joined: 2017